Imatinib is a standard treatment for Philadelphia (Ph) chromosome-positive chronic myeloid leukemia (CML), but its efficacy in rare BCR::ABL variants is underexplored. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.